TIPS for Budd-Chiari Syndrome
TIPS should be performed in Budd-Chiari syndrome patients who fail to respond to anticoagulation therapy or when hepatic vein interventions are not technically feasible. 1
Treatment Algorithm
Step 1: Initial Management at Specialized Centers
All BCS patients must be managed at centers with high expertise—either liver transplant centers or facilities with formal transplant center links 1. This is non-negotiable given the complexity and rarity of the condition.
Step 2: First-Line Therapy
- Anticoagulation is the initial treatment for all BCS patients
- Hepatic vein interventions (angioplasty/stenting) should be attempted in symptomatic patients when technically feasible 1
Step 3: TIPS Indication
TIPS is indicated when:
- Patients fail to improve with anticoagulation therapy (strong recommendation) 1
- Hepatic vein interventions are unsuccessful or not technically possible 1
- Acute presentation with diffuse hepatic vein occlusion 1
The 2020 BSG/BASL/BSIR guidelines provide the most current framework, superseding the 2010 AASLD recommendations that were based on a single retrospective study 2.
Expected Outcomes
The evidence strongly supports TIPS efficacy in BCS:
- Technical success: 98.6% 3
- Clinical success: 90.3% 3
- 1-year transplant-free survival: 88% 2, 4
- 5-year transplant-free survival: 78% 4
- 10-year transplant-free survival: 69% 2
These outcomes are substantially better than predicted by prognostic scores alone, suggesting TIPS improves survival even in high-risk patients 4.
Technical Considerations
Stent Selection
Use covered (ePTFE) stents preferentially 2. The evidence shows:
- Superior primary patency rates with covered stents
- Reduced shunt dysfunction compared to bare metal stents
- Better long-term outcomes 2, 1
Special Scenarios
- Diffuse hepatic vein occlusion: TIPS remains technically feasible with 100% technical success reported, though more challenging 5
- Direct intrahepatic portocaval shunt (DIPS): Alternative technique when all hepatic veins are occluded, with similar clinical outcomes to standard TIPS 1
Patient Selection and Contraindications
Proceed with TIPS if:
- BCS-TIPS prognostic index score ≤7 6
- Moderate prognosis by MELD, Child-Pugh, and Rotterdam BCS scores 6
Consider early liver transplant assessment if:
- Poor prognostic scores (bilirubin, age, INR predict 1-year survival) 4
- BCS-TIPS prognostic score >7 (associated with 87.5% mortality/transplant rate) 4
- No response to anticoagulation and radiological therapies 1
- Acute liver failure presentation 1
Complications and Monitoring
Expected Complications
- Hepatic encephalopathy: 11.6% (considerably less than cirrhotic patients, up to 15% reported) 1, 3
- Major adverse events: 10% 3
- TIPS-related mortality: 0.5% 3
Surveillance Protocol
For BCS patients with prothrombotic conditions:
- Doppler ultrasound at 1 week post-TIPS (mandatory) 1
- TIPSS venography as determined by interventional radiologist 1
- Regular follow-up imaging given higher dysfunction risk
Critical Pitfall
Do not delay TIPS in patients failing medical therapy. The mortality rate in BCS patients who don't receive TIPS after failing anticoagulation is 88.9%, compared to 6.59% in those who undergo TIPS 5. Early intervention is crucial.
Pre-Procedure Workup
Before TIPS placement, obtain:
- Cross-sectional imaging of liver and vessels
- Liver and kidney function tests
- Coagulation studies
- Cardiac evaluation (ECG, NT-proBNP, echocardiogram if abnormal)
- Nutritional assessment
- Hepatic encephalopathy screening 1
Long-Term Management
- Lifelong anticoagulation is required in all BCS patients, including post-TIPS 7
- TIPS dysfunction rate: 40.1% overall, necessitating close surveillance 3
- TIPS revision needed: 8.6% of patients 3
- Liver transplant rate: 4.5% despite TIPS 3
The stepwise approach (anticoagulation → hepatic vein intervention → TIPS → liver transplant) provides excellent outcomes for most BCS patients, with TIPS serving as a highly effective bridge or definitive therapy 8, 7.